Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

Aim: The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). Methods: This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. Results: A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; p = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; p = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; p < 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; p = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; p = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; p = 0.833). The main reason was administration by injection. Conclusion: Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management.

Download Full-text

Pregabalin use in HIV-infected patients with opioid dependence syndrome

V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY ◽

10.31363/2313-7053-2018-2-70-79 ◽

2018 ◽

pp. 70-79 ◽

Cited By ~ 1

Author(s):

M. Ya. Kissin ◽

N. B. Khalezova ◽

E. A. Gibitova ◽

A. V. Tarnorutskaya ◽

A. N. Ivanov

Keyword(s):

Opioid Dependence ◽

Cross Sectional Study ◽

Opioid Use Disorder ◽

Toxic Exposure ◽

Opioid Use ◽

Self Medication ◽

Cross Sectional ◽

Entire Cohort ◽

Long Time ◽

And Control

Te purpose of the current study was to identify an abuse potential of pregabalin in HIVinfected patients with opioid use disorder long time using pregabaline. A cross-sectional study was performed at the St. Petersburg Center for the prevention and control of HIV and infectious diseases. A cohort of 572 HIV-infected patients with opioid use disorder was examined. 96 patients (16,8% of the entire cohort) used pregabalin. 34 of them agreed to participate in the study. Te pregabalin addiction was diagnosed in 23 of 34 observed HIV-infected patients with opioid dependence. People with opioid dependence and presence of organic brain damage of various genesis (toxic exposure, neurological consequences of trauma or infection) are at risk of development of pregabalin dependence. Te use of pregabalin with for self-medication of opiod withdrawal was registered in 11 patients.

Download Full-text

Opioid Use Disorder during Antepartum and Postpartum Hospitalizations

American Journal of Perinatology ◽

10.1055/s-0039-1694725 ◽

2019 ◽

Vol 37 (14) ◽

pp. 1467-1475

Author(s):

Adina R. Kern-Goldberger ◽

Yongmei Huang ◽

Melanie Polin ◽

Zainab Siddiq ◽

Jason D. Wright ◽

...

Keyword(s):

Opioid Dependence ◽

Nationwide Inpatient Sample ◽

Temporal Trends ◽

Opioid Use Disorder ◽

Opioid Overdose ◽

Opioid Use ◽

Chi Square ◽

Cross Sectional ◽

Chi Square Test ◽

Sectional Analysis

Objective This study aimed to evaluate temporal trends in opioid use disorder (OUD) during antepartum and postpartum hospitalizations. Study Design This repeated cross-sectional analysis analyzed data from the National (Nationwide) Inpatient Sample. Women aged 15 to 54 years admitted antepartum or postpartum were identified. The presence of OUD was determined based on a diagnosis of opioid abuse, opioid dependence, or opioid overdose. Temporal trends in OUD were evaluated using the Rao–Scott chi-square test. Temporal trends in opioid overdose were additionally evaluated. Results An estimated 7,336,562 antepartum hospitalizations and 1,063,845 postpartum readmissions were included in this analysis. The presence of an OUD diagnosis during antepartum hospitalizations increased from 0.7% of patients in 1998 to 1999 to 2.9% in 2014 (p < 0.01) and during postpartum hospitalizations increased from 0.8% of patients in 1998 to 1999 to 2.1% of patients in 2014 (p < 0.01). Risk of overdose diagnoses increased significantly for both antepartum hospitalizations, from 22.7 per 100,000 hospitalizations in 1998 to 2000 to 70.3 per 100,000 hospitalizations in 2013 to 2014 (p < 0.001), and postpartum hospitalizations, from 18.8 per 100,000 hospitalizations in 1998 to 2000 to 65.2 per 100,000 hospitalizations in 2013 to 2014 (p = 0.02). Discussion Risk of OUD diagnoses and overdoses increased over the study period for both antepartum and postpartum hospitalizations.

Download Full-text

Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment

Drug and Alcohol Dependence ◽

10.1016/j.drugalcdep.2021.108857 ◽

2021 ◽

pp. 108857

Author(s):

Gabriel Bastien ◽

Claudio Del Grande ◽

Alina Dyachenko ◽

Janusz Kaczorowski ◽

M. Gabrielle Pagé ◽

...

Keyword(s):

Research Design ◽

Discrete Choice Experiment ◽

Discrete Choice ◽

Choice Experiment ◽

Opioid Use Disorder ◽

Opioid Use ◽

Comorbid Depression ◽

Cross Sectional

Download Full-text

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18041425 ◽

2021 ◽

Vol 18 (4) ◽

pp. 1425

Author(s):

Morgane Guillou-Landreat ◽

Antoine Dany ◽

Gaëlle Challet-Bouju ◽

Edouard Laforgue ◽

Juliette Leboucher ◽

...

Keyword(s):

Clinical Practice ◽

Opioid Use Disorder ◽

Term Treatment ◽

Pharmacological Therapy ◽

Daily Clinical Practice ◽

Short Report ◽

Opioid Use ◽

Cross Sectional ◽

Long Term Treatment ◽

Social Profiles

(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment. Pharmacological therapy for OUD involves treatment with opioid agonists (OMT) tailored to individual profiles. The aim of our study in daily clinical practice was to compare the profiles of patients treated with methadone (MTD) and those using buprenorphine (BHD or BHD-naloxone-NX). (2) Methods: A cross-sectional multicentre study explored the psychological, somatic and social profiles of patients with Opioid Use Disorder (OUD) following Opioid Maintenance Treatment (BHD, BHD/NX, or MTD). Descriptive and comparative analyses were performed (3) Results: 257 patients were included, a majority were men using heroin. 68% (178) were on MTD, 32% (79) were on BHD. Patients with MTD were significantly more likely to report socio-affective damage, and more likely to be younger and not to report oral or sublingual use as the main route for heroin or non-medical opioids (4) Conclusions: In daily clinical practice, regarding OUD damage, only socio-affective damage was significantly more prevalent among patients on MTD than among those on BHD in the multivariate model. Age and route of administration also differed, and our results could raise the issue of the type of OMT prescribed in case of non-medical use of prescribed opioids. These hypothesis should be confirmed in larger studies.

Download Full-text

Primary Care of Opioid use Disorder: The End of “the French Model”?

European Addiction Research ◽

10.1159/000506630 ◽

2020 ◽

Vol 26 (6) ◽

pp. 346-354 ◽

Cited By ~ 1

Author(s):

Julie Dupouy ◽

Sandy Maumus-Robert ◽

Yohann Mansiaux ◽

Antoine Pariente ◽

Maryse Lapeyre-Mestre

Keyword(s):

Primary Care ◽

Private Practice ◽

Primary Care Providers ◽

Opioid Use Disorder ◽

Care Providers ◽

Opioid Use ◽

Access To Treatment ◽

Cross Sectional ◽

Number Of Patients ◽

French Model

Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,297 from 61,301 French private GPs) prescribed buprenorphine for the initiation of a treatment, whereas they were 5.7% (n = 3,539 from 62,071 private GPs) in 2015 (43.8% decrease). GPs issuing initial prescriptions of buprenorphine tended to care for a higher number of patients treated by buprenorphine (14.6 ± 27.1 patients in 2009 to 16.0 ± 35.4 patients in 2015). The number of CPs dispensing buprenorphine remained quite stable (decrease of 2%), while there was a 7.5% decrease in the total number of French CPs across the study period. Conclusions: Our results suggest that primary care providers seem less engaged in buprenorphine initiation in OUD patients, while CPs have not modified their involvement towards these patients.

Download Full-text

Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross‐sectional study of a state all‐payer claims database

Journal of Public Health Dentistry ◽

10.1111/jphd.12488 ◽

2021 ◽

Author(s):

Lisa Simon ◽

Abhishek Choudhary ◽

Shenam Ticku ◽

Jane Barrow ◽

Matthew Tobey

Keyword(s):

Dental Care ◽

Cross Sectional Study ◽

Opioid Use Disorder ◽

Care Utilization ◽

Sectional Study ◽

Opioid Use ◽

Cross Sectional ◽

Claims Database ◽

Dental Care Utilization ◽

Before And After

Download Full-text

Health care utilization and overall costs based on opioid dependence in patients undergoing surgery for degenerative spondylolisthesis

Neurosurgical FOCUS ◽

10.3171/2018.2.focus17764 ◽

2018 ◽

Vol 44 (5) ◽

pp. E14 ◽

Cited By ~ 5

Author(s):

Mayur Sharma ◽

Beatrice Ugiliweneza ◽

Zaid Aljuboori ◽

Maxwell Boakye

Keyword(s):

Health Care ◽

Health Care Utilization ◽

Opioid Dependence ◽

Degenerative Spondylolisthesis ◽

Opioid Use Disorder ◽

Hospital Length Of Stay ◽

Care Utilization ◽

Opioid Use ◽

Opioid Dependency ◽

Linear Contrasts

OBJECTIVEOpioid abuse is highly prevalent in patients with back pain. The aim of this study was to identify health care utilization and overall costs associated with opioid dependence in patients undergoing surgery for degenerative spondylolisthesis (DS).METHODSThe authors queried the MarketScan database using ICD-9 and CPT-4 codes from 2000 to 2012. Opioid dependency was defined as having a diagnosis of opioid use disorder, having a prescription for opioid use disorder, or having 10 or more opioid prescriptions. Opioid dependency was evaluated in 12-month period leading to surgery and in the period 3–15 months following the procedure. Patients were segregated into 4 groups based on opioid dependence before and after surgery: group NDND (prior nondependent who remain nondependent), group NDD (prior nondependent who become dependent), group DND (prior dependent who become nondependent), and group DD (prior dependent who remain dependent). The outcomes of interest were discharge disposition, hospital length of stay (LOS), complications, and health care resource costs. The 4 groups were compared using the Kruskal-Wallis test and linear contrasts built from generalized regression models.RESULTSA total of 10,708 patients were identified, with 81.57%, 3.58%, 8.54%, and 6.32% of patients in groups NDND, NDD, DND, and DD, respectively. In group DD, 96.31% of patients had decompression with fusion, compared with 93.59% in group NDND. Patients in group NDD, DND, and DD had longer hospital LOS compared with those in group NDND. Patients in group DD were less likely to be discharged home compared with those in group NDND (odds ratio 0.639, 95% confidence interval 0.52–0.785). At 3–15 months postdischarge, patients in group DD incurred 21% higher hospital readmission costs compared with those in group NDND. However, patients in groups NDD and DD were likely to incur 2.8 times the overall costs compared with patients in group NDND (p < 0.001) at 3–15 months after surgery (median overall payments: group NDD $20,033 and group DD $19,654, vs group NDND $7994).CONCLUSIONSPatients who continued to be opioid dependent or became opioid dependent following surgery for DS incurred significantly higher health care utilization and costs within 3 months and in the period 3–15 months after discharge from surgery.

Download Full-text

Use of Buprenorphine for the Treatment of Opioid Use Disorder

Substance Use Disorders ◽

10.1093/med/9780190920197.003.0009 ◽

2020 ◽

pp. 155-168

Author(s):

Paul J. Fudala ◽

Anne Cramer Andorn

Keyword(s):

Opioid Dependence ◽

Addiction Treatment ◽

Partial Agonist ◽

The United States ◽

Opioid Use Disorder ◽

Sublingual Administration ◽

Opioid Use ◽

The Us ◽

Monthly Administration ◽

Drug Addiction Treatment

Buprenorphine is a mu-opioid partial agonist that was first developed as a parenteral analgesic and subsequently as a treatment for opioid dependence. In the United States, the first two products approved by the US Food and Drug Administration (in 2002) for the latter indication were buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) tablet formulations for sublingual administration. Since that time, additional products for both sublingual and buccal administration have also been approved, as well as a subcutaneous injection for once-monthly administration for the treatment of moderate or severe opioid use disorder (OUD) and a subdermal implant for the maintenance treatment of opioid dependence that delivers buprenorphine over a 6-month period. Under the Drug Addiction Treatment Act of 2000 (DATA 2000), qualified practitioners may apply for waivers to treat opioid dependence/OUD with approved buprenorphine products in any setting in which they are qualified to practice. Like other opioids, buprenorphine has the potential for being misused and abused.

Download Full-text